Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.40 |
| ▸ | MMP2 | P08253 | 2/20 | 0.40 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | ACACA | Q13085 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12531578 | 0.98 | SMN1; SMN2 (0.39) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| 1,6-Hexanediol SCHEMBL4564056 | 0.95 | LMNA (0.46) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL483813 | 0.95 | LMNA (0.46) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL897366 | 0.95 | LMNA (0.46) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL554611 | 0.95 | LMNA (0.46) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL12491170 | 0.95 | LMNA (0.46) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL6888416 | 0.95 | LMNA (0.46) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL20680773 | 0.95 | LMNA (0.46) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL887706 | 0.95 | LMNA (0.46) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL10007983 | 0.95 | LMNA (0.46) | LMNAALDH1A1HSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062720-A1 | Multifunctional Fatty Acid Derivatives And Biosynthesis Thereof | AGAIN BIO APS (DK) | 2026-03-05 | — | — | US | disclosed |
| US-20240309405-A1 | MULTIFUNCTIONAL FATTY ACID DERIVATIVES AND BIOSYNTHESIS THEREOF | OXFORD FINANCE LLC | 2024-09-19 | — | — | US | disclosed |
| US-20210189439-A1 | Multifunctional Fatty Acid Derivatives And Biosynthesis Thereof | GENOMATICA, INC. (US) | 2021-06-24 | — | — | US | disclosed |
| EP-3810778-A1 | MULTIFUNCTIONAL FATTY ACID DERIVATIVES AND BIOSYNTHESIS THEREOF | Genomatica, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| WO-2019217226-A1 | MULTIFUNCTIONAL FATTY ACID DERIVATIVES AND BIOSYNTHESIS THEREOF | REG Life Sciences, LLC (US) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062720-A1 | Multifunctional Fatty Acid Derivatives And Biosynthesis Thereof | FASN, FFAR1, FFAR3 | LMNA 3981/4885ALDH1A1 398/4885HSD17B10 27/4885 |
| US-20240309405-A1 | MULTIFUNCTIONAL FATTY ACID DERIVATIVES AND BIOSYNTHESIS THEREOF | DGAT2, DGAT1, FASN | LMNA 4765/4885ALDH1A1 1172/4885HSD17B10 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.